A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2 α in Patients with Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: ARO-HIF2 downregulated HIF2α in advanced ccRCC-inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.PMID:38652038 | DOI:10.1158/1078-0432.CCR-23-3029 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: James Brugarolas Gregory Obara Kathryn E Beckermann Brian Rini Elaine T Lam James Hamilton Thomas Schluep Min Yi So Wong Zhongping Lily Mao Erick Gamelin Nizar M Tannir Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
Classifying glioma via liquid biopsy--progress towards an unmet clinical need
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0423. Online ahead of print.ABSTRACTThe diagnosis and classification of glioma by liquid biopsy represents a critical unmet need in neuro oncology. A recent study demonstrates targeted next generation sequencing (NGS) of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) as an evolving option for liquid biopsy in patients with glioma.PMID:38652677 | DOI:10.1158/1078-0432.CCR-24-0423 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Kalil G Abdullah Source Type: research
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
CONCLUSIONS: Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy.PMID:38652812 | DOI:10.1158/1078-0432.CCR-24-0210 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Dickran Kazandjian Benjamin Diamond Marios Papadimitriou Elizabeth Hill Romanos Sklavenitis-Pistofidis Bachisio Ziccheddu Patrick Blaney Monika Chojnacka Michael Durante Kylee Maclachlan Ryan Young Saad Usmani Faith Davies Gad Getz Irene Ghobrial Neha Kor Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study
CONCLUSIONS: Utilizing the split-course hypo-RT and hypo-boost approach, a fraction dose of 5Gy to a total dose of 60Gy, combined with concurrent chemotherapy and subsequent cICI, was well-tolerated, and yielded promising ORR and survival outcomes.PMID:38652815 | DOI:10.1158/1078-0432.CCR-23-3600 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Rui Zhou FangJie Liu HongMei Zhang DaQuan Wang PengXin Zhang ShiYang Zheng YiMei Liu Li Chen JinYu Guo YingYi Zou Yu-Ming Rong Hui Liu Bo Qiu Source Type: research
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
CONCLUSIONS: ML modeling effectively subclassified patients with BCLC-C HCC, potentially aiding treatment allocation. Our study underscores the potential utilization of ML modeling in terms of prognostication and treatment allocation in patients with BCLC-C HCC.PMID:38639918 | DOI:10.1158/1078-0432.CCR-23-3978 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Ji Won Han Soon Kyu Lee Jung Hyun Kwon Soon Woo Nam Hyun Yang Si Hyun Bae Ji Hoon Kim Heechul Nam Chang Wook Kim Hae Lim Lee Hee Yeon Kim Sung Won Lee Ahlim Lee U Im Chang Do Seon Song Seok-Hwan Kim Myeong Jun Song Pil Soo Sung Jong Young Choi Seung Kew Y Source Type: research
Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma
CONCLUSIONS: Collectively, our findings suggest NeoVax did stimulate expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine-based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in GBM patients.PMID:38639919 | DOI:10.1158/1078-0432.CCR-23-3077 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Tanner M Johanns Elizabeth A R Garfinkle Katherine E Miller Alexandra J Livingstone Kaleigh F Roberts Lakshmi Prakruthi Rao Venkata Joshua L Dowling Michael R Chicoine Ralph G Dacey Gregory J Zipfel Albert H Kim Elaine R Mardis Gavin P Dunn Source Type: research
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11
CONCLUSION: We were unable to prospectively validate candidate SNPs previously associated with AI discontinuation due to AIMSS. Future analyses will explore additional genetic markers, PRO predictors of AIMSS, and differences by race.PMID:38640040 | DOI:10.1158/1078-0432.CCR-23-2137 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Vered Stearns Opeyemi A Jegede Victor Tsu-Shih Chang Todd C Skaar Jeffrey L Berenberg Ranveer Nand Atif Shafqat Nisha Lassi Jacobs William Luginbuhl Paul Gilman Al B Benson Judie R Goodman Gary L Buchschacher N Lynn Henry Charles L Loprinzi Patrick J Flyn Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Monitoring hepatocellular carcinoma using tumor content in circulating cell-free DNA
CONCLUSIONS: The tumor content in ccfDNA is correlated with tumor burden and may help in monitoring HCC one year earlier than clinical diagnosis and in predicting patient prognosis.PMID:38630548 | DOI:10.1158/1078-0432.CCR-23-3449 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Shifeng Lian Chenyu Lu Fugui Li Xia Yu Limei Ai Biao-Hua Wu Xueyi Gong Wenjing Zhou Xuejun Liang Jiyun Zhan Yong Yuan Fang Fang Zhiwei Liu Mingfang Ji Zongli Zheng Source Type: research
Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
CONCLUSION: While in cohort A pembrolizumab lacked activity, cohort B and cohort C met the study's primary endpoint. Further research is warranted to refine selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity.PMID:38630551 | DOI:10.1158/1078-0432.CCR-24-0011 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Birgit S Geurts Laurien J Zeverijn Lindsay V M Leek Jade M van Berge Henegouwen Louisa R Hoes Hanneke van der Wijngaart Vincent van der Noort Joris van de Haar Annemiek van Ommen-Nijhof Marleen Kok Paul Roepman Anne M L Jansen Wendy W J de Leng Maja J A d Source Type: research
A cohort study of CNS tumors in Multiple Endocrine Neoplasia Type 1
CONCLUSIONS: Incidence of each CNS tumor was higher in the MEN1 population than in the French general population. Meningiomas and ependymomas should be considered part of the MEN1 syndrome, but somatic molecular data are missing to conclude for astrocytomas and schwannomas.PMID:38630553 | DOI:10.1158/1078-0432.CCR-23-3308 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Thomas Graillon Pauline Romanet Clara Camilla Camille Gelin Romain Appay Catherine Roche Arnaud Lagarde Gr égory Mougel Kaissar Farah Ma ëlle Le Bras Julien Engelhardt Michel Kalamarides Matthieu Peyre Aymeric Amelot Evelyne Emery Elsa Magro Helene Cebu Source Type: research
Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations
CONCLUSIONS: Together, this approach offers a potential treatment strategy for patients with EGFRm-driven NSCLC that have a sub-optimal response, or develop resistance, to osimertinib through PIK3CA/AKT/PTEN alterations.PMID:38630555 | DOI:10.1158/1078-0432.CCR-23-2540 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O'Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclova Matthew J Martin Ludovic Bigot Luc Friboulet Ryan Hartmaier Maria Emanuela Cuomo Simon T Barry Paul D Smith Nicolas Floc'h Source Type: research
Low-dose ionizing γ-radiation elicits the extrusion of neutrophil extracellular traps
CONCLUSIONS: NETosis is induced by low-dose ionizing irradiation in a neutrophil-intrinsic fashion and radiation-induced NETs are able to interfere with immune-mediated cytotoxicity. Radiation-induced NETs foster metastasis in mouse models and can be detected in the circulation of patients undergoing conventional radiotherapy treatments.PMID:38630754 | DOI:10.1158/1078-0432.CCR-23-3860 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Alvaro Teijeira Saray Garasa Maria C Ochoa Sandra Sanchez-Gregorio Gabriel Gomis Carlos Luri-Rey Rafael Martinez-Monge Beatrice Pinci Karmele Valencia Belen Palencia Benigno Barbes Elixabet Bolanos Arantza Azpilikueta Marina Garcia-Cardosa Javier Burguete Source Type: research
